<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Does Congress Need A Lesson On Biotechnology or Economics?</title>
	<atom:link href="http://www.patentbaristas.com/archives/2008/08/13/does-congress-need-a-lesson-on-biotechnology-or-economics/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.patentbaristas.com/archives/2008/08/13/does-congress-need-a-lesson-on-biotechnology-or-economics/</link>
	<description>Freshly Brewed Bio/Pharma Chat. Served Up Daily.</description>
	<lastBuildDate>Thu, 18 Mar 2010 11:54:35 -0400</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<item>
		<title>By: Recent Faves Tagged With "protein" : MyNetFaves</title>
		<link>http://www.patentbaristas.com/archives/2008/08/13/does-congress-need-a-lesson-on-biotechnology-or-economics/comment-page-1/#comment-65582</link>
		<dc:creator>Recent Faves Tagged With "protein" : MyNetFaves</dc:creator>
		<pubDate>Mon, 09 Feb 2009 20:50:02 +0000</pubDate>
		<guid isPermaLink="false">http://www.patentbaristas.com/archives/2008/08/13/does-congress-need-a-lesson-on-biotechnology-or-economics/#comment-65582</guid>
		<description>[...] &gt;&gt; protein    Calories in K2O Protein Water First saved by HieiShadowNinjaZX &#124; 5 days ago      Does Congress Need A Lesson On Biotechnology or Economics? First saved by TennesseeHickChick &#124; 12 days ago      Protein Bars Are Not Gadgets But… First [...]</description>
		<content:encoded><![CDATA[<p>[...] &gt;&gt; protein    Calories in K2O Protein Water First saved by HieiShadowNinjaZX | 5 days ago      Does Congress Need A Lesson On Biotechnology or Economics? First saved by TennesseeHickChick | 12 days ago      Protein Bars Are Not Gadgets But… First [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: BiologicsMan</title>
		<link>http://www.patentbaristas.com/archives/2008/08/13/does-congress-need-a-lesson-on-biotechnology-or-economics/comment-page-1/#comment-64342</link>
		<dc:creator>BiologicsMan</dc:creator>
		<pubDate>Thu, 02 Oct 2008 14:12:41 +0000</pubDate>
		<guid isPermaLink="false">http://www.patentbaristas.com/archives/2008/08/13/does-congress-need-a-lesson-on-biotechnology-or-economics/#comment-64342</guid>
		<description>There is no need for a shortcut in the PHS Act..the law only requirement on FDA is that it licensure of a biolgics be based on critiera established by FDA as necessary to assure the safety, purity...of the product.

There is a long history of FDA approving new biologics based on an essentially generic basis 
-- blood and blood products
-- allergenic products meeting compendial standards
--certain vaccines
-- ....

The arguement that &quot;biotech products&quot; are too complicated falls apart when you consider that biologics/natural products/peptides under the FDC Act have been generics or 505b2, that there are a great many small molecular drugs that have narrow therapeutic index, complex delivery/bioavalibility and synthesis/identity issues (think warfarin, conjugated estrogens and heparin).</description>
		<content:encoded><![CDATA[<p>There is no need for a shortcut in the PHS Act..the law only requirement on FDA is that it licensure of a biolgics be based on critiera established by FDA as necessary to assure the safety, purity&#8230;of the product.</p>
<p>There is a long history of FDA approving new biologics based on an essentially generic basis<br />
&#8211; blood and blood products<br />
&#8211; allergenic products meeting compendial standards<br />
&#8211;certain vaccines<br />
&#8211; &#8230;.</p>
<p>The arguement that &#8220;biotech products&#8221; are too complicated falls apart when you consider that biologics/natural products/peptides under the FDC Act have been generics or 505b2, that there are a great many small molecular drugs that have narrow therapeutic index, complex delivery/bioavalibility and synthesis/identity issues (think warfarin, conjugated estrogens and heparin).</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: aarp</title>
		<link>http://www.patentbaristas.com/archives/2008/08/13/does-congress-need-a-lesson-on-biotechnology-or-economics/comment-page-1/#comment-60213</link>
		<dc:creator>aarp</dc:creator>
		<pubDate>Tue, 19 Aug 2008 06:25:10 +0000</pubDate>
		<guid isPermaLink="false">http://www.patentbaristas.com/archives/2008/08/13/does-congress-need-a-lesson-on-biotechnology-or-economics/#comment-60213</guid>
		<description>[...] the campaign by Insmed??s chief exec, Geoffrey Allan, to give Congress a lesson in biotechnologyhttp://www.patentbaristas.com/archives/2008/08/13/does-congress-need-a-lesson-on-biotechnology-or-ec...Gallatin AARP promotes medical emergency project The TennesseanThe Gallatin chapter of aarp is [...]</description>
		<content:encoded><![CDATA[<p>[...] the campaign by Insmed??s chief exec, Geoffrey Allan, to give Congress a lesson in biotechnologyhttp://www.patentbaristas.com/archives/2008/08/13/does-congress-need-a-lesson-on-biotechnology-or-ec&#8230;Gallatin AARP promotes medical emergency project The TennesseanThe Gallatin chapter of aarp is [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>
